Lighthouse Pharmaceuticals, Inc. — SEC Form D Filing
Lighthouse Pharmaceuticals, Inc. filed an SEC Form D on May 7, 2026, reporting $15.21M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- May 7, 2026
- Amount reported
- $15.21M
- Round stage
- Series A
- Industry
- Pharmaceuticals
- Website
- https://www.lighthousepharma.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Patients with Alzheimer's disease associated with P. gingivalis face major unmet medical needs due to inadequate current treatments.
Solution
Lighthouse Pharmaceuticals is developing LHP588, a next-generation gingipain inhibitor targeting P. gingivalis-positive Alzheimer's disease.
Why now
There is a growing demand for innovative treatments in Alzheimer’s disease, especially for subtypes that are currently under-addressed.
Verdict
Investors backed Lighthouse Pharmaceuticals because the focus on a specific unmet need in Alzheimer's treatment presented a clear narrative, not because the competitive landscape was free from significant players. The implicit bet was on the therapeutic promise of LHP588 as a novel intervention against an emerging understanding of disease pathology. However, the limited upside lies in the crowded and competitive biopharma space, where established names dominate, putting pressure on long-term market penetration and differentiation.
Source: SEC EDGAR Form D filing